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A B S T R A C T
Background
Psychosexual dysfunction (sexual difficulties not directly due to physical factors) is known to be a common complication of treatment
for gynaecological cancer. It has a considerable impact on quality of life (QoL) for the increasing number of women who are survivors
of gynaecological cancer.
Objectives
To determine the effectiveness of interventions for psychosexual dysfunction in women who have been treated for gynaecological
malignancy (cancer of uterine cervix, uterine corpus, ovary, vulva).
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL, up to October 2008), MEDLINE (1950 to October
2008), EMBASE (1982 to October 2008), CINAHL (1980 to October 2008) and PsycINFO (1806 to October 2008). We hand
searched reference lists from eligible trials.
Selection criteria
We selected all randomized controlled trials (RCTs) of a medical or psychological intervention to prevent or treat psychosexual
dysfunction in adult women previously treated for gynaecological cancer.
Data collection and analysis
We selected five studies for inclusion in this review and analysed any outcome data relating to resumption of sexual intercourse, DSM-
IV diagnoses or validated scales of sexual functioning. Sensitivity analysis was performed where possible.
Main results
The review included data from 5 studies, comprising a total of 413 patients, examining 5 different interventions. One trial suggested
a short-term benefit for the use of vaginal Dienoestrol in women after pelvic radiotherapy (NNT = 4). Another trial suggested a short-
term benefit for one regime of low dose-rate brachytherapy over another but this modality is not in widespread use. Studies of a Clinical
Nurse Specialist intervention, Psychoeducational Group Therapy and a Couple-Coping intervention, did not show any significant
benefit. All the studies were of poor methodological quality.
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Authors’ conclusions
There is no convincing evidence to support the use of any interventions for psychosexual dysfunction inwomen treated for gynaecological
cancer. There is a need for more studies of high methodological quality.
P L A I N L A N G U A G E S U M M A R Y
Interventions for psychosexual dysfunction in women treated for gynaecological malignancy
This systematic review found very few good quality trials of interventions to treat or prevent psychosexual problems occurring in
women after treatment for gynaecological cancer. They were mostly small studies and all examined different types of interventions.
This review found only weak evidence to support the use of vaginal oestrogen, some low dose-rate brachytherapy regimes and a number
of psychological interventions.
B A C K G R O U N D
Gynaecological cancers (cancer of the vulva, cervix, uterus, and
ovary) can have a profound effect on the sexual function of women
(Corney 1992; Corney 1993; Crowther 1994). The treatment for
many is radical surgery, which can be both physically and psycho-
logicallymutilating. For example, womenwith cervical cancerwho
have a radical hysterectomy or pelvic radiotherapy may experience
shortening of the vagina and absence of lubrication during inter-
course resulting in pain (Bergmark 1999a). Although the mutila-
tion caused by radical vulvar surgery is profound, womenmay also
suffer adverse effects on sexual functioning from the treatment of
cancer of the ovary or uterus by hysterectomy, oophorectomy and
chemotherapy and the resulting oestrogen deficiency. Impaired
sexual function is undoubtedly multifactorial and psychological
reactions to gynaecological cancer can cause problems with sexual
functioning. These may include: disturbances of mood, gender
and sexual identity, and body-image; loss of control over body sys-
tems; disturbance of normal opportunities for intimate behaviour;
and loss of fertility (Weijmar-Schultz 1990). Even the develop-
ment of symptoms of gynaecological cancer and its diagnosis have
been associated with adverse effects on sexual function (Anderson
1986).
Up to 63% of patients over 55 years and 37% of those under
55 years of age treated for gynaecological cancer are not sexually
active after treatment (Thranov 1994). Even allowing for the ob-
vious confounders of age and prior sexual activity, this measure
may be an underestimate of sexual problems after gynaecologi-
cal cancer. Studies based on post-treatment report of symptoms
have found rates of sexual problems ranging from six to 100%
(Weijmar-Schultz 1990). Since sexuality itself is not an objective
measure, it follows that the assessment of sexual function is sub-
jective and must be operationalized based on ideal and real ex-
periences. Restarting sexual activity is not synonymous with re-
sumption of a fulfilling sexual relationship, just as the anatomical
possibility of sexual function does not guarantee resumption of
satisfactory sexual activity. Much research does assume an existing
heterosexual relationship, raising doubts about its appropriateness
for women in lesbian relationships or those not in a relationship
at all.
Since the concept of sexuality for women is broader than anatom-
ical function and encompasses effects on relationships and sex-
ual self-concept (Butler 1998), psychosexual therapies have been
utilised to help restore satisfactory sexual function. To our knowl-
edge there have been no other systematic reviews of this topic and
so it is appropriate for the effectiveness of those therapies which
have thus far been subjected to controlled trials to be assessed.
O B J E C T I V E S
To determine the effectiveness of interventions for psychosexual
dysfunction in women who have been treated for gynaecological
malignancy.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
Randomised controlled trials (RCTs) of any form of physical, psy-
chological and/or pharmacological treatmentwere eligible for con-
sideration providing that they compared the intervention either
with another treatment, placebo treatment or non-intervention
(e.g. waiting list controls).
Types of participants
Participants in the studies had to be exclusively female or the data
for female subjects had to be accessible. All had to have had a
primary malignancy of the female genital tract i.e. vulva, vagina,
cervix, corpus uteri, fallopian tube or ovary. Those with metastases
in the genital tract from an extra-genital primary were excluded as
they differ considerably in treatment and prognosis from primary
gynaecological malignancies.
Participants were eligible for inclusion if they were aged over 16
years and had demonstrable psychosexual dysfunction or distress
at entry to the study. These could include the DSM-IV diagnoses
of Dyspareunia (302.76), Female Orgasmic Disorder (302.73),
Female Sexual Arousal Disorder (302.72), Hypoactive Sexual De-
sire Disorder (302.71), Sexual Aversion Disorder (302.79) and
Vaginismus (306.51) (APA 1994).
The method of diagnosis could include the sexual activity ques-
tionnaire (Stead 1999) as well as instruments of Quality of Life
(QoL) and psychological symptoms such as the Short Form 36
Hamilton Rating Scale (Ware 1993), Hospital Anxiety and De-
pression Scale (Zigmond 1983), General Health Questionnaire
(Goldberg 1997) and the BeckDepression Inventory (Steer 1999).
Types of interventions
Any psychological or medical interventions to prevent or treat
psychosexual dysfunction were considered in this review. Psycho-
logical treatments such as educational therapies, behavioural tech-
niques and cognitive therapies were considered along with hybrid
therapies of one or more of these combined with another interven-
tion. Medical treatments considered included vaginal oestrogen
therapy, different radiotherapy regimes to try to ameliorate their
effects on sexual function, the use of vaginal dilators to maintain
vaginal capacity and the use of a clitoral therapy device to improve
vaginal blood flow.
Types of outcome measures
Tobe included for consideration studies had to have as an outcome
measure the resumption of sexual activity as measured by self-
report, partner report, or sexual activity questionnaire. Since the
resumption of sexual activity alone does not necessarily equate to
a satisfying relationship, improvement on any form of rating scale
validated in a comparable patient set was also accepted as a valid
outcome measure.
Search methods for identification of studies
Electronic searches
1. Initially the Cochrane Review Group’s Specialised register
was checked to identify all potentially eligible studies (Last
checked 18/10/08).
2. The following electronic databases were searched to identify
potentially eligible studies and review articles: CENTRAL
(Cochrane Library, MEDLINE (1950 to October 2008),
CINAHL (1982 to October 2008), EMBASE (1980 to October
2008), PsycINFO (1806 to October 2008), the Database of
Abstracts of Reviews of Effectiveness (DARE), and Biological
Abstracts (January 1980 to October 2008). Searches were carried
out using the online search engine OvidSP and utilised the filter
for RCTs as described in the Cochrane Handbook for Reviewers
(Cochrane Handbook). Any potentially relevant non-English
language papers were translated.
3. The search strategy for OvidSP is in Appendix 1.
Searching other resources
1. The reference lists of all potentially relevant articles
retrieved, as well as those of systematic reviews, were checked to
identify other potentially relevant articles. These articles were
retrieved and assessed for possible inclusion in the review.
2. Personal communications - the lead author of all relevant
papers identified was emailed or written to in order to ascertain if
they knew of any additional published or unpublished studies
that might be relevant to the review.
The search strategies have been developed and executed by the
author.
Data collection and analysis
Selection of studies
Trials were selected for inclusion in the review after independent
assessment by two review authors and additional information was
sought, if required, from the authors of the selected trials.
Two review authors (FK and PF) independently selected suitable
studies for inclusion in this review as detailed below. Where the
two review authors disagreed about the inclusion of a study, dis-
agreements were resolved by a consensus of opinion, and although
a third review author (SK) was available for arbitration, this was
not required.
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The titles and abstracts of studies identified by searching electronic
databases were assessed to determine whether each article met the
eligibility criteria. In order to prevent any bias, a list of all titles and
abstracts was printed out excluding the authors’ names, institu-
tions and journal titles. If a title and abstract contained sufficient
information to determine that the article did not meet the inclu-
sion criteria, then it was rejected. A record of all rejected papers
was kept and the reasons for rejection were documented.
The full papers of all remaining titles and abstracts deemed rel-
evant were then retrieved. In addition, all other potentially rele-
vant articles identified by the various search strategies (reference
checking, personal communications etc) were also reviewed. Any
potentially relevant papers in languages other than English were
translated and reviewed by someone who spoke the language. All
articles were reviewed independently by two of the review authors,
who completed a form for each study and scored the quality of the
research as defined below. The reasons for exclusion were docu-
mented. Where the same study had more than one article written
about the outcomes, all articles were treated as one study and the
results were presented only once.
Data extraction and management
The two review authors (PF, FK) completed the extraction of data
from the papers on to a form to elicit the following information:
• general: published/unpublished, title, authors, source,
contact address, country, language of publication, year of
publication, duplicate publications, sponsoring, setting (hospital
inpatients, primary care, community)
• trial characteristics: design, duration, randomisation and
method, allocation concealment and method, blinding of
outcome assessors, check of blinding
• interventions: frequency, timing, comparison interventions,
co-medications
• patient characteristics: sampling, exclusion criteria, number
of participants, age, sex, ethnicity, marital status, educational
status, duration of symptoms, number of complications,
similarity of groups at baseline (including any co-morbidity),
withdrawals/losses to follow-up (reasons/descriptions)
• type of psychiatric co-morbidity: clinical diagnosis or
symptomatology assessed by questionnaires
• type of assessment tool used to assess quality of life
psychiatric co-morbidity: e.g. Beck Depression Inventory, Zung
Depression scale, Hospital Anxiety and Depression Scale,
Structured Interview, DSM-IV criteria
• type of intervention: psychological, pharmacological,
medical or surgical; usual care versus intervention; ’attention’
placebo versus intervention.
• type of outcomes: resumption of sexual activity, as
measured by self report interview or sexual activity questionnaire
and possibly verified by the partner, improvement in relevant
validated scales of QoL and psychological symptoms
• timing of follow-up: short, medium or long-term
• assessment of methodological quality: method of
randomisation used, if stated, method of allocation concealment
(adequate, unclear, inadequate or allocation concealment not
used); blinding of outcome assessors (yes, no, unclear); and
patients lost to follow-up (cut off 20% attrition or more);
intention to treat analysis.
Assessment of risk of bias in included studies
Assessment of the quality of a particular trial will be made in
accordance with guidelines in the Cochrane Handbook.
Assessment of the method of randomisation
To prevent selection bias, someone who is not responsible for
recruiting the participants, such as a central trial office or someone
not involved in the trial, should conduct the randomisation. The
method of randomisation was noted on the data extraction form.
Assessment of the degree of blinding (treatment and
outcome assessment) and allocation concealment
Allocation concealment was assessed as described in the Cochrane
Handbook. This is as follows:
A - adequate description of the allocation procedure,
B - unclear description of the allocation procedure,
C - inadequate description of the allocation procedure and
D - allocation concealment was not used.
If the review authors disagreed over which category a trial was al-
located to, resolution was attempted by discussion or by obtaining
further information. In addition, review authors were blinded to
the authors’ names, institutions and journal title to prevent any
bias.
Losses to follow-up
The paper should have given an adequate description of the loss of
its participants in terms of the number of withdrawals, dropouts
and protocol deviations. Had any study had losses to follow-up of
more than 20% of those originally randomised, these data would
have been presented as a sub-group, but this was not required.
Assessment of reporting biases
Had the trial interventions been directly comparable the data
would have been entered into a funnel plot (size of study versus
size of effect) (Egger 1997) to attempt to detect the possibility of
publication bias. Since the identified studies all addressed different
interventions this was not assessable.
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Data synthesis
Data Entry
Data was entered into RevMan software by PF and duplicated by
FK. The data extracted from included studies was summarised.
Data Types
Depending on the type of study the outcomes were assessed using
continuous (for example, changes in depression scales), categorical
(for example, one of three categories on a QOL scale, such as
’better’, ’worse’, or ’no change’), or dichotomous (for example
either sexually active or not sexually active) measures.
Continuous data: Many rating scales are available to measure out-
comes in psychological trials. These scales varied in the quality
of their validation and reliability. Therefore, if a rating scale’s val-
idation had not been published in a peer-reviewed journal then
the data was not included in this review. In addition, the rating
scale should have been either self-report or completed by an in-
dependent observer or relative. It was planned that any trials that
had used the same instrument to measure specific outcomes were
compared directly. If continuous datawas presented fromdifferent
scales rating the same effect both sets of data were to be presented
and the general direction of the effect inspected. The mean and
standard deviation (SD) were reported. Where SDs were not re-
ported in the paper, attempts were made to obtain them from the
authors or to calculate them using other measures of variation that
are reported, such as the confidence intervals (CIs). If possible,
meta-analysis was considered for data from different scales rating
the same effect using the Standardised Mean Difference (SMD).
Dichotomous data: Continuous outcome measures were con-
verted to dichotomous data where necessary. If the authors of the
study used a designated cut-off point for determining clinical ef-
fectiveness the review authors used this where appropriate. Other-
wise, cut-offs on rating scales were identified and participants were
divided on the basis of whether they were ’clinically improved’ or
’not clinically improved’. For dichotomous outcomes, a Mantel-
Haenszel odds ratio (OR) with its associated 95% CI was esti-
mated. As a summary measure of effectiveness, where possible the
number needed to treat statistic (NNT) was also calculated.
Subgroup analysis and investigation of heterogeneity
In the review protocol sub group analyses were planned to con-
sider:
• Differences between studies, which define sexual activity,
QOL, and psychiatric symptoms operationally (clinician
diagnosis or validated questionnaire and whether validated in
this specific population or in other groups).
• Differences between studies that include partner’s views and
those that do not.
• Differences between types of interventions (psychological,
pharmacological, medical or surgical) and types of controls.
• Differences between well-defined and less well-defined
psychological interventions.
As the studies included in this review did not lend themselves
to aggregation, sub-group analysis was not possible. A review of
heterogeneity was not required since only one trial was identified
for each type of intervention.
Sensitivity analysis
The reliability of the conclusions of the review was tested with
sensitivity analyses of the data where possible. The data for each
study was re-analysed using different models (fixed-effect instead
of random-effect), altering substitutions for any missing data, and
excluding trials of low methodological quality. If any of these had
changed the results significantly then the conclusions might have
been of lesser validity.
R E S U L T S
Description of studies
Results of the search
A search of electronic databases using the previously described
search strategy yielded 1559 citations. Examination of the titles
and abstracts of these produced 12 that were potentially eligible
but examination of the full text of these articles allowed us to
exclude 7 non-RCT or uncontrolled studies. Examination of the
reference lists of the five remaining eligible studies yielded one ad-
ditional study that was published as an abstract only. Correspon-
dence with the author who had recently retired did not yield suf-
ficient information for it to be included in the review. Further in-
formation was requested from the authors of the five studies above
but only one reply was received, which did not provide any more
useful information. As some of these studies were published some
time ago, the corresponding authors may have moved to another
institution or retired. Should any further information be obtained
from them it will be included in future review updates.
Included studies
Topical oestrogen prophylaxis for post-Irradiation vaginal
complications
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A small (n = 93) placebo-controlled study in 1971 evaluated the
vaginal administration of Dienoestrol 0.01% cream after comple-
tion of primary radiotherapy for carcinoma of the cervix (Pitkin
1971). Patient report of dyspareunia was just one of the outcomes
examined, as well as vaginal bleeding, with other outcomes being
assessed by clinical examination. Satisfaction with intercourse, or
any other aspect of sexual function was not examined in this study
that took a rather anatomical approach to sexuality. No baseline
assessment of sexual function was performed but the reported rate
of sexual activity (60%) is rather low compared to other studies,
although this may have been more typical of its era.
Low dose-rate brachytherapy regimens in cervix cancer
One French study examined the morbidity outcomes in a trial
population (n = 204) where two different dose-rates (0.4 Gy/hr
and 0.8 Gy/hr) for pre-operative vaginal brachytherapy were used
prior to radical hysterectomy (Haie-Meder 1994). A previous pub-
lication reported the results with regard to mortality and recur-
rence (which were similar in both arms) so it is likely that the mor-
bidity outcomes were not a primary outcome of the study. The
method of treatment is one that is not in widespread use in the
UK, the use of remote after-loading devices delivering high dose-
rate therapy having superseded low dose rate brachytherapy. Sim-
ilarly, the use of radiotherapy in a neoadjuvant setting such as this
is not routine in UK practice but may be in other countries. Low
dose-rate therapy is in use in certain countries including France
and the conclusions of this study are of relevance for these areas.
Clinical nurse specialist intervention
In this small UK single-blind RCT of patients of mixed tumour
sites, the intervention arm received a pre-surgery consultationwith
a psychosexually-trained gynaecological oncology specialist nurse
and were visited by her at home on an average of three further
occasions after surgery (Maughan 2001). The intervention is not
described in detail and no checks on adherence to the intervention
by the therapist were described. The control arm received standard
nursing care only but were referred to specialist services if they re-
ported any problems at follow-up visits. A qualitative study based
on patient interviews was conducted in parallel with the RCT, but
it should be noted that they interviewed nearly twice as many from
the control group as the intervention group. Since the interviews
could have had some therapeutic effect, this is a potential limita-
tion of this study. The EORTC QLQ-30 questionnaire and the
Lasry Sexual Functioning Scale were used to assess the outcomes.
Psychoeducational group therapy
A single small (n = 40) RCT trial conducted in Canada had as its
primary outcome whether the intervention would improve com-
pliance with the use of vaginal dilators after radiotherapy treat-
ment for FIGO stage 1 or 2 cervix or corpus cancer (Robinson
1999). A variety of other treatments were received and, no doubt
due to the small size of this study, the arms were not well balanced
for other treatments. The mean age of the control group was also
higher (51 versus 43) but the groups were similar in other respects.
The intervention arm received two 90-minute group counselling
sessions based on the Intervention-Motivation-Behavioural Skills
model while the controls had a single one-to-one meeting with a
counsellor who provided an information leaflet. There is no de-
scription of the level of training of the therapists and although
there is some description of the information component, it is un-
clear whether there was a prescribed methodology for the other
components and, if so, whether any checks on therapist adherence
were performed. Follow-up was carried out by means of self-com-
pletion of the Sexual History Form by post and a global score was
calculated (SHF-GS).
Couple-Coping Intervention.
This study from Australia randomised 94 women with breast and
gynaecological cancers to one of three treatment arms medical
information education; patient coping training; or CanCope, a
couple coping intervention (Scott 2004). Those receiving medical
information education received booklets and five 15-minute tele-
phone calls in the 9 months after surgery. Patient coping training
consisted of four 2-hour counselling sessions in the patient’s home
followed up by two 30-minute telephone calls. CanCope involved
the patient and her partner in five 2-hour counselling sessions in
their home followed by two 30-minute telephone calls. The thera-
pists were extensively experienced in this field and followed a treat-
ment manual. Sessions were audiotaped and a random selection
reviewed to ensure adherence with protocols. The outcome was
assessed using self-administered questionnaires returned by post,
including the Brief Index of Sexual Function (BISF) and the Psy-
chosocial Adjustment to Illness - Self Report (PAIS-SR) Sexual
Difficulties subscale.
Risk of bias in included studies
The five studies included were all of poor methodological quality.
The reasons for the decision in each case are explained below.
Topical oestrogen prophylaxis for post-irradiation vaginal
complications
This study is unclear regarding the precise method of randomisa-
tion used, but the allocation concealment was graded as A, with
the allocation only being revealed after completion of the trial. A
placebo cream was used that was provided by the manufacturer
and was identical in both presentation and composition (other
than the active ingredient dienosetrol) to the treatment cream.
Those assessing outcomes were also blinded, although the method
of assessment (patient symptom report to doctor) is likely to have
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poorer ascertainment than methods such as validated question-
naires. The authors do not report any losses to follow-up and as-
sume 100% compliance with treatment and as a result have per-
formed an intention to treat (ITT) analysis without describing it
as such. Such a compliance rate is surprising and is a weakness
of this study. During sensitivity analysis, the inclusion of all trial
participants in analysis led to the treatment effect becoming non-
significant creating some doubt on the reliability of the findings.
Overall this trial is not of high methodological quality.
Low dose-rate brachytherapy in cervical cancer
Much of the methodology of this trial is unclear and further clar-
ification is awaited. The method of randomisation is unclear, al-
though the allocation concealment is described and appears to
have been adequate (grade A). Assessors were blinded to the out-
comes but the method of ascertainment of complications was not
described in detail and may have tended to underestimate adverse
events. No mention is made of losses to follow-up or protocol de-
viations and it is therefore impossible to say whether an ITT anal-
ysis was performed. In view of these problems this study cannot
be regarded as being of high methodological quality, although this
may be revised if and when further information becomes available.
Clinical Nurse Specialist intervention
The Maughan 2001 study was very small and there is no record
of any power calculation. Although the description of allocation
was adequate, the method of randomisation does not appear to
have attempted to stratify for the confounding effects of tumour
sites and adjuvant therapies. As a result there was an imbalance
between the control and intervention arms sufficient to cancel
out any treatment effect. There was no description of the alloca-
tion concealment and the description of the study suggests that it
was not used and should be graded D. The running of a parallel
qualitative study was a potentially important source of bias since
the qualitative assessment was also not balanced between the trial
arms and it could potentially have influenced outcomes. As the
assessment of the trial outcomes was by means of mailed back self-
report questionnaires, the blinding of outcome assessors was not
required. Two patients who died (one in each arm) were excluded
from the analysis of the trial and the analysis was therefore not
by ITT. Re-analysis after substitution for the missing patients did
not make any significant difference to the conclusions. Because
of serious potential biases this study must be regarded as being of
poor methodological quality.
Psychoeducational group therapy
This study does not provide detail of the randomisation process
other than referring to a random number table. The concealment
of allocation is unclear at best and was graded C. Although most
of the assessments were by means of self-report questionnaires, it
is unclear whether there was adequate blinding of outcome asses-
sors for one of the outcomes, that of compliance with vaginal di-
lation. As the latter was not an outcome of interest for this study,
this doubt does not therefore affect significantly the reliability of
this study. The major methodological flaw with this study is the
extremely high drop out rate (20%, 3 controls, 5 interventions)
that in the authors’ own words means that this trial ight better be
described as a non-equivalent controlled trial. Although some of
these dropouts did return their initial baseline questionnaires these
were not included in the analysis and therefore the analysis was
not by intention to treat. The investigators carried out an analy-
sis of baseline equivalence and found that the baseline SHF-GS
scores were significantly lower in the experimental group (mean
difference = -0.132, t(29) = 3.41, p = 0.0019). This trial should
be regarded as of very poor methodological quality and the results
interpreted with great caution.
Couple coping Intervention
Themainmethodological difficulty with this study in terms of this
review is that it has not been possible to distinguish the outcomes
for gynaecological cancer patients from those for breast cancer pa-
tients. As a result all conclusions must refer to both groups and
since gynaecological cancers were the minority it is possible that
a strong effect in breast cancer patients could conceal no effect in
gynaecological patients and vice versa. The method of randomi-
sation is unclear and no method of concealment of allocation ap-
pears to have been undertaken (Grade D). Blinding of the assess-
ment of outcomes was achieved by the use of self-report question-
naires. There was an extremely high dropout rate (21% of women
and 30% of their partners) and there is no information provided
on whether this was evenly distributed across the study arms. The
analysis was not by intention to treat and because of the limited
data published it was not possible to re-analyse using substitution
of the missing data. On the basis of the information available this
trial was of very poor methodological quality.
Effects of interventions
The five studies in this review all trialed different interventions
and did not utilise the same outcome measures and so cannot be
directly compared. Meta-analysis is therefore not appropriate and
the results of the studies will be presented individually.
Topical oestrogen prophylaxis for post-irradiation vaginal
complications
A smaller proportion of those in the intervention group reported
dyspareunia (6/44) than in the placebo group (16/49) but al-
though the authors reported that this did not reach statistical sig-
nificance with chi-square testing (P = 0.09), our analysis suggested
that there was a significant difference with an OR of 0.33 (95%
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CI 0.11 to 0.93) (Analysis 1.1). Among the 26 patients in the
intervention group who were sexually active, the majority (20) re-
ported no dyspareunia and the remainder reported mild dyspare-
unia only. Of the 30 in the control arm reported to be sexually
active, 14 denied dyspareunia, 16 reported dyspareunia, of whom
6 graded it as severe. When the sexually active participants were
analysed separately with dyspareunia as an outcome measure, a
greater treatment effect was demonstrated (OR = 0.26, 95% CI
0.08 to 0.84) (Analysis 1.2). As the follow-up in this study lasted
only slightly longer than the treatment (mean 6.9 months) a tem-
porary effect that was not maintained after treatment ended can-
not be excluded. There were no losses to follow-up reported.
Low dose-rate brachytherapy regimens in cervix cancer
As the study of vaginal oestrogen above, this report has no infor-
mation about pre-morbid sexual function and determines com-
plications according to those reported to clinicians at follow-up
visits. No losses to follow-up were reported but the paper does not
explicitly state that there were none. The only outcome measure
to relate to sexual function is that of dyspareunia and no data is
included regarding the proportion who were sexually active. The
overall prevalence of dyspareunia is low (11.8%) but other gynae-
cological morbidities are reported such as pelvic sclerosis, inconti-
nence, fistula and vaginal necrosis, all of which would significantly
impair sexual function. Overall prevalence of dyspareunia was sig-
nificantly lower in the 0.4 Gy/hr group (OR = 0.37, 95% CI 0.15
to 0.93) Analysis 2.1. The paper also states that dyspareunia had
resolved in the majority of both groups by 25 months after treat-
ment and by this stage the differences were no longer significant
(OR = 0.39, 95% CI 0.07 to 2.05) Analysis 2.2. These findings
are consistent with an amelioration of short-term side-effects of
brachytherapy without a significant long-term benefit.
Clinical Nurse Specialist intervention
Subjects were assessed at 6, 12 and 24 weeks post surgery using the
EORTC QLQ-30 and the Lasry Sexual Functioning Scale, both
validated instruments. Unfortunately, no score data was published
and our efforts to obtain this are ongoing. The authors report
no significant differences between the groups in any of the sexual
functioning scales examined and although the rates of resumption
of intercourse in those previously sexually active showed a trend
towards benefit this was not statistically significant (OR = 0.63,
95% CI 0.17 to 2.36) Analysis 3.1. Significantly less of the in-
tervention group (2/10 versus 9/10) had diminished satisfaction
with intercourse six months after their surgery (OR = 0.03, 95%
CI 0.00 to 0.37) Analysis 3.2 but it should be noted that there was
an excess of patients having adjuvant therapy in the control group.
These women might well have had a much shorter treatment-free
interval and could well be expected to be at an earlier stage in
their recovery than women who had surgery alone. Few conclu-
sions should be drawn from this, especially given the very small
numbers involved. The only losses to follow-up were because of
death, suggesting that this intervention is acceptable to patients.
Psychoeducational group therapy
The mean pre-treatment SHF-GS for the intervention group was
0.401 (SD = 0.081) and that of the control 0.513 (SD = 0.126),
both of which are comparable with the norms for healthy women.
The SHF-GS data for follow-up visits are only reported in graph-
ical form with the comment that there was no evidence that the
intervention had an impact on post intervention scores. This state-
ment is prefaced with “After controlling for baseline scores...” so
additional data is being sought from the authors to see how this
was carried out. Although the trial did seem to demonstrate an
effect on improved compliance with dilation in those followed up,
the drop-out rate of 20% may indicate that either the therapy or
the use of dilators was unacceptable to a significant minority. The
effect on compliance did not translate into any improvement in
sexual function.
Couple-coping intervention
This study excluded those who had a psychological disorder within
the past year as well as those whowere not in a committed relation-
ship, raising doubts about whether any conclusions can be gen-
eralised. The authors did not present the data for gynaecological
cancer patients separately and this additional information has not
yet been received, so no analysis of this study has been possible.
Overall participants in the trial showed no significant difference in
all subscales bar the BISF Sexual Intimacy subscale where women
who received CanCope reported less of a decrease in sexual inti-
macy (mean = -1.21, SD = 2.5) than women receiving medical
information education (mean = -3.53, SD = 2.55) or patient cop-
ing training (mean = -2.36, SD = 2.53). As there appeared to be
no significant effect on overall sexual function, the significance of
this effect on intimacy is questionable.
D I S C U S S I O N
This review has highlighted the difficulty in making evidence-
based treatment decisions in this field. Five eligible trials were
identified, most small, and all with poor methodology. Only two
showed any demonstrable treatment effect but as one of these
refers to a treatment modality that is not in widespread use, only
one study has potential for widespread clinical application.
Vaginal oestrogen cream is a simple treatment which showed a
short-term benefit in cervix cancer patients (Pitkin 1971). Unfor-
tunately, as the numbers of cervix cancers are reduced by screening
in developed countries, corpus cancer, whose incidence is rising, is
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becoming themost common indication for vaginal brachytherapy.
Oestrogens are generally avoided in corpus cancer because of con-
cerns that it may stimulate growth of the tumour cells which often
have oestrogen receptors. Vaginal oestrogen is therefore likely to be
of benefit to a only small subset of gynaecological cancer sufferers.
Low dose-rate brachytherapy prior to Radical Hysterectomy may
be associated with a lower rate of dyspareunia in the short term
(Haie-Meder 1994). Although a long-term benefit would be de-
sirable even a short-term reduction of dyspareunia may help in
reducing long-term psychosexual difficulties. This finding is of
little utility to UK clinicians who do not commonly give pre-op-
erative radiotherapy for operable cervical cancers and since high
dose-rates are generally used for brachytherapy performed as part
of radical radiotherapy, these findings are not applicable in UK
practice.
ClinicalNurse Specialists are an integral part of theGynaecological
Oncology Multidisciplinary Team in the UK. Their unique role
puts them in an ideal position to be the first point of contact for
gynaecological cancer patients regarding psychosexual difficulties.
Maughan’s study (Maughan 2001) is to be applauded for seeking
to develop an evidence base for this work but trials many times
the size of this one will be needed to give adequate power. This
study does illustrate the difficulties that such studies will have in
ensuring proper blinding.
A psychoeducational group therapy has demonstrated increased
compliance with vaginal dilators but this did not translate into
benefit in terms of a significant improvement in SHF-GS scores
(Robinson 1999). This finding is unsurprising as dilation itself
merely maintains anatomical normality and does not address the
complex psychosocial issues that treatment for gynaecological can-
cer involves. Anatomical preservation is, however, an advantage in
restoring sexual function so this intervention may be worthwhile
as part of a package of measures addressing sexual function but
this is outside the scope of this review.
Generally interventions that treat couples as opposed to individ-
uals might be more successful in restoring a satisfactory sexual re-
lationship. The absence of demonstrable benefit in this study of
a couple-coping intervention (Scott 2004) should not discourage
further research on couple-based interventions. Investigative re-
search into the role of the partner of gynaecological cancer patients
may provide directions for potential interventions.
It is disappointing how few RCTs were found in this review. This
does raise the question of whether the ascertainment of trials was
complete andwhether there aremore eligible trials that have simply
failed to be found by this review. Further sources of studies include
foreign language databases and abstracts of conference proceedings
but there is often a law of diminishing returns with ever-wider
searches. Given that the search so far has revealed so few eligible
studies, it is doubtful but possible that further studies exist.
There is no shortage of interventions to be trialed as we identified
a number of studies that, being non-RCTs, were ineligible for this
review. Capone et al performed a non-RCT of 56 patients who
received individual counselling during their hospital stay from a
psychologist, incorporating a sexual rehabilitation component for
those who had been sexually active (Capone 1980). Compared to
a historical control group of 41 patients, a significantly higher pro-
portion of those counselled had resumed their previous frequency
of intercourse up to12months after treatment (84%versus 42.9%,
p < 0.05). The role of vaginal stent dilation for those who have
had radiotherapy was explored in one study of 35 patients given a
perspex stent after treatment (Decruze 1999). A lower incidence
of vaginal stenosis as assessed by clinical examination was found in
this group compared to a historical control group who had simply
been advised to have regular intercourse. No outcomes in terms
of sexual function were reported. The diversity of interventions
identified in this review demonstrates that the management of
sexual dysfunction requires attention to many factors, physical,
psychological and social and future research should take this into
account.
So why have so few RCTs been performed in this area? There is
little doubt that this is an extremely sensitive area of which few
have made a specialty in the past. While Clinical Psychologists
and Psychosexual Therapists would undoubtedly have an interest
in these problems, in some healthcare systems e.g. the UK, these
servicesmay not be sufficiently resourced as yet formost patients to
be referred to them. Furthermore, these services are usually set up
to deal with women and couples who do not have cancer and may
not be in a position to offer specialised care for the problems that
are specific to women who have been treated for a gynaecological
cancer. In the UK, Clinical Nurse Specialists are now an essential
part of the multidisciplinary teams treating gynaecological cancer
and see psychosexual care as an integral part of their role. It is
encouraging to note that one of the included studies was carried
out by a Clinical Nurse Specialist and this may be the route by
which future RCTs are organised.
As this review demonstrates, a good quality RCT is not an easy
thing to carry out in this field and requires considerable support
from clinical and non-clinical staff. There is an urgent need to
develop suitable interventions that can be trialled since, as has
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been demonstrated by this review, there are very few tools avail-
able for the treatment of psychosexual morbidity in this group of
women. Trials of psychological interventions are needed and as
such interventions often require considerable amounts of the time
of highly skilled practitioners, these trials are likely to be expensive
and difficult to organise. It may be worthwhile for future trials to
be organised on a multi-centre basis as this enables a number of
centres to share resources and is more likely to attract the necessary
funding.
The poor methodological quality of all the trials in this review
is also disappointing. There is no doubt that the multi-factorial
aetiology of psychosexual dysfunction means that there is a wealth
of potential confounding factors to be considered by investigators
of potential treatments. The consistent use of the same outcome
measures in future trials would benefit future meta-analysis of
results and this could perhaps be promoted by a group such as
the International Gynaecological Cancer Society which could also
provide the numbers required to achieve statistical power.
Since there may be significant differences between patients with
different tumour sites, future trials should, where possible, be re-
stricted to individual tumour sites. Where this is not possible, the
trial should be powered for subgroup analysis by tumour site as an
intervention that works well with a 40 year old cervical cancer pa-
tient may not work well with a 65 year old ovarian cancer patient.
Particular attention should also be given to ensuring adequate
blinding in future studies to avoid potential bias. This may be
particularly difficult with psychotherapies, since the duration and
nature of the interaction with the therapist may reveal the alloca-
tion, but this bias could be avoided by having outcomes assessed
by a third party observer, unaware of treatment allocation. With
a number of the trials follow-up was up to 12 months and in two
studies the benefit from treatment seemed to reduce with time.
It is important that future studies ensure sufficiently long-term
follow-up so that short-term effects can be identified.
It is clear from the results section of this review that further in-
formation regarding on a number of the studies would be useful
in interpreting both their validity and reliability. It is hoped that
some of these trial authors will be located and that the information
will be obtained to update the review further.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to support or refute the use of any
interventions for psychosexual dysfunction after gynaecological
cancer.
Implications for research
There is a need formulti-centre RCTs with outcomemeasures that
have been validated in gynaecological cancer patients. When con-
sidering interventions to trial, we would suggest that investigators
should focus on interventions that can be delivered by existing
members of the multidisciplinary team treating women with gy-
naecological cancers. It is more likely that such measures, if found
effective, will be affordable and capable of being integrated into
standard care. An international consensus on outcome measures
would greatly facilitate the comparison of interventions in the fu-
ture.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Haie-Meder 1994
Methods RCT with local control rate, overall and progression-free survival as primary endpoints
Participants Pre-operative patients with Stage I-IIA cervix cancer (n=204)
Interventions Neoadjuvant low dose-rate brachytherapy at 0.4Gy/hr versus 0.8Gy/hr
Outcomes Dyspareunia recorded in a physician-administered questionnaire
Notes Modality not used in some countries including UK. Randomisation method not described
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? Low risk A - Adequate
Blinding?
All outcomes
Low risk
Free of other bias? High risk Some relevant baseline characteristics not reported.
Maughan 2001
Methods RCT performed alongside qualitative study
Participants Women undergoing treatment for a variety of gynaecological cancers (n=36)
Interventions One pre-surgery consultation and 3 home visits by Nurse Specialist versus standard
nursing care
Outcomes Self-report questionnaires (EORTC QLQ-30, Lasry Sexual Functioning Scale)
Notes Significant differences between groups in terms of cancer treatment received. Adequate
randomisation method
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk
Allocation concealment? Low risk
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Maughan 2001 (Continued)
Blinding?
All outcomes
High risk
Incomplete outcome data addressed?
All outcomes
Low risk
Free of other bias? High risk Not intention-to-treat analysis.
Pitkin 1971
Methods Placebo-controlled trial
Participants Women with no residual disease after radiotherapy for cervix cancer stages I-IV (n=93)
Interventions Vaginal oestrogen cream versus placebo cream
Outcomes Self-report of dyspareunia
Notes Short follow-up (range 5-8 months, median 6.9). Inadequate description of randomisa-
tion
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk
Allocation concealment? Low risk A - adequate
Blinding?
All outcomes
Low risk
Incomplete outcome data addressed?
All outcomes
Low risk
Free of selective reporting? Low risk
Free of other bias? Low risk
Robinson 1999
Methods Randomised controlled trial
Participants Women having pelvic radiotherapy for cervix or endometrial cancers, stages I-II (n=40)
Interventions Two 1.5 hour counselling sessions versus single meeting with counsellor + leaflet
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Robinson 1999 (Continued)
Outcomes Sexual History Form Global Score (SHF-GS) and self-report compliance with vaginal
dilation
Notes Only 32 patients analysed - not intention to treat. Partial description of randomisation
process
Risk of bias
Bias Authors’ judgement Support for judgement
Adequate sequence generation? Low risk
Allocation concealment? Unclear risk C- Inadequate
Incomplete outcome data addressed?
All outcomes
High risk
Free of selective reporting? High risk
Scott 2004
Methods Randomised controlled trial
Participants 37 women undergoing treatment for gynaecological cancer and their partners
Interventions Couple-Coping Therapy (5x2hr sessions at home and 2x30min phone calls) versus
Medical Information Education (Booklet; 5x15min phone calls) versus Patient Coping
Training (4x2hr sessions at home; 2x30min phone calls)
Outcomes Brief Index of Sexual Functioning (BISF) self-report scale
Notes Randomisation method not described. High proportion lost to follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Allocation concealment? High risk C - Inadequate
Blinding?
All outcomes
High risk
Incomplete outcome data addressed?
All outcomes
High risk
Free of selective reporting? High risk
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bergmark 1999 Retrospective descriptive study
Booth 1996 No outcome measure relating to sexual function
Capone 1980 Non-randomised study using historical controls
Cartwright-Alcarese 1995 Non-systematic review
Decruze 1999 Non-randomised study using historical controls
Gothard 2005 Non-randomised Phase II study
Kikku 1982 Uncontrolled study
Landoni 1985 Non-randomised study using historical controls
Schroder 2005 Uncontrolled Phase II study
16Interventions for psychosexual dysfunction in women treated for gynaecological malignancy (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Vaginal oestrogen versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Dyspareunia in all patients 1 93 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.11, 0.93]
2 Dyspareunia in sexually active 1 56 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.08, 0.84]
Comparison 2. Brachytherapy 0.4Gy/Hr versus 0.8Gy/hr
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Dyspareunia in all patients 1 204 Odds Ratio (M-H, Fixed, 95% CI) 0.37 [0.15, 0.93]
2 Dyspareunia at 25 months post
treatment
1 204 Odds Ratio (M-H, Fixed, 95% CI) 0.39 [0.07, 2.05]
Comparison 3. Clinical Nurse Specialist versus Standard Care
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Not sexually active 1 36 Odds Ratio (M-H, Fixed, 95% CI) 0.63 [0.17, 2.36]
2 Previously active, unsatisfactory
now
1 20 Odds Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.37]
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Analysis 1.1. Comparison 1 Vaginal oestrogen versus placebo, Outcome 1 Dyspareunia in all patients.
Review: Interventions for psychosexual dysfunction in women treated for gynaecological malignancy
Comparison: 1 Vaginal oestrogen versus placebo
Outcome: 1 Dyspareunia in all patients
Study or subgroup Oestrogen Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pitkin 1971 6/44 16/49 100.0 % 0.33 [ 0.11, 0.93 ]
Total (95% CI) 44 49 100.0 % 0.33 [ 0.11, 0.93 ]
Total events: 6 (Oestrogen), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 1.2. Comparison 1 Vaginal oestrogen versus placebo, Outcome 2 Dyspareunia in sexually active.
Review: Interventions for psychosexual dysfunction in women treated for gynaecological malignancy
Comparison: 1 Vaginal oestrogen versus placebo
Outcome: 2 Dyspareunia in sexually active
Study or subgroup Oestrogen Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Pitkin 1971 6/26 16/30 100.0 % 0.26 [ 0.08, 0.84 ]
Total (95% CI) 26 30 100.0 % 0.26 [ 0.08, 0.84 ]
Total events: 6 (Oestrogen), 16 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 2.1. Comparison 2 Brachytherapy 0.4Gy/Hr versus 0.8Gy/hr, Outcome 1 Dyspareunia in all patients.
Review: Interventions for psychosexual dysfunction in women treated for gynaecological malignancy
Comparison: 2 Brachytherapy 0.4Gy/Hr versus 0.8Gy/hr
Outcome: 1 Dyspareunia in all patients
Study or subgroup 0.4Gy/hr 0.8Gy/hr Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Haie-Meder 1994 7/102 17/102 100.0 % 0.37 [ 0.15, 0.93 ]
Total (95% CI) 102 102 100.0 % 0.37 [ 0.15, 0.93 ]
Total events: 7 (0.4Gy/hr), 17 (0.8Gy/hr)
Heterogeneity: not applicable
Test for overall effect: Z = 2.11 (P = 0.035)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 Brachytherapy 0.4Gy/Hr versus 0.8Gy/hr, Outcome 2 Dyspareunia at 25 months
post treatment.
Review: Interventions for psychosexual dysfunction in women treated for gynaecological malignancy
Comparison: 2 Brachytherapy 0.4Gy/Hr versus 0.8Gy/hr
Outcome: 2 Dyspareunia at 25 months post treatment
Study or subgroup 0.4Gy/hr 0.8Gy/hr Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Haie-Meder 1994 2/102 5/102 100.0 % 0.39 [ 0.07, 2.05 ]
Total (95% CI) 102 102 100.0 % 0.39 [ 0.07, 2.05 ]
Total events: 2 (0.4Gy/hr), 5 (0.8Gy/hr)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 Clinical Nurse Specialist versus Standard Care, Outcome 1 Not sexually active.
Review: Interventions for psychosexual dysfunction in women treated for gynaecological malignancy
Comparison: 3 Clinical Nurse Specialist versus Standard Care
Outcome: 1 Not sexually active
Study or subgroup CNS intervention Standard care Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maughan 2001 9/19 10/17 100.0 % 0.63 [ 0.17, 2.36 ]
Total (95% CI) 19 17 100.0 % 0.63 [ 0.17, 2.36 ]
Total events: 9 (CNS intervention), 10 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 3.2. Comparison 3 Clinical Nurse Specialist versus Standard Care, Outcome 2 Previously active,
unsatisfactory now.
Review: Interventions for psychosexual dysfunction in women treated for gynaecological malignancy
Comparison: 3 Clinical Nurse Specialist versus Standard Care
Outcome: 2 Previously active, unsatisfactory now
Study or subgroup CNS intervention Standard care Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Maughan 2001 2/10 9/10 100.0 % 0.03 [ 0.00, 0.37 ]
Total (95% CI) 10 10 100.0 % 0.03 [ 0.00, 0.37 ]
Total events: 2 (CNS intervention), 9 (Standard care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0065)
Test for subgroup differences: Not applicable
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A P P E N D I C E S
Appendix 1. Search Strategy for OvidSP
1. Randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8
10 humans.sh.
11. 9 and 10
12. Gyn?ecologi$.mp.
13. Female genital.mp.
14. Ovar$.mp.
15. Fallopian tube.mp.
16. Uter$.mp.
17. Corpus.mp.
18. Endometri$.mp.
19. Cervi$.mp.
20. Vagin$.mp.
21. Vulv$.mp.
22. Cancer.mp.
23. Carcinoma.mp.
24. Sarcoma.mp.
25. Malignancy.mp.
26. exp Genital Neoplasms, Female/
27. exp Sexual Dysfunctions, Psychological/
28. Dyspareunia/
29. Sexual.mp.
30. Psychosexual.mp.
31. Intercourse.mp.
32. Dyspar?unia.mp.
33. Orgas$.mp.
34. cognitive behavio?ral therapy.mp.
35. (cognitive adj2 therapy).mp.
36. counsel?ing.mp.
37. psychodynamic.mp.
38. relaxation therapy.mp.
39. desensiti?ation.mp.
40. rational emotive therapy.mp.
41. antidepressant?.mp.
42. sildenafil.mp.
43. 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21
44. 22 or 23 or 24 or 25
45. 43 and 44
46. 45 or 26
47. 27 or 28 or 29 or 30 or 31 or 32 or 33
48. 46 and 47 and 11
Key - mp=title, original title, abstract, name of substance word, subject heading word
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Brachytherapy; Estrogens [therapeutic use]; Genital Neoplasms, Female [psychology; ∗therapy]; Patient Education as Topic; Psychother-
apy [methods]; Randomized Controlled Trials as Topic; Sexual Dysfunctions, Psychological [etiology; ∗therapy]
MeSH check words
Female; Humans
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